1. Record Nr. UNINA9910166853503321

Autore	Cozzolino, Salvatore <1954- >
Titolo	Teorie di progetto ambientale attraverso l'Europa / Salvatore Cozzolino, Lucio Nardi, Renata Valente
Pubbl/distr/stampa	Napoli : CLEAN, 2014
ISBN	978-88-8497-494-5
Descrizione fisica	95 p. ; 24 cm
Collana	Tecnologia e progetto
Altri autori (Persone)	Valente, Renata Nardi, Lucio
Disciplina	711.094
Locazione	FARBC
Collocazione	URB.LE B 3018
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia

2. Record Nr. UNICAMPANIAVAN00252866

Autore	Valongo, Alessia <1968->
Titolo	Aspetti dell'autonomia negoziale procedimentale : il preliminare di preliminare / Alessia Valongo
Pubbl/distr/stampa	Napoli, : Edizioni scientifiche italiane, 2022
ISBN	978-88-495-4880-8
Descrizione fisica	256 p. ; 21 cm
Soggetti	Contratti preliminari - Italia
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia

3. Record Nr. UNINA9910557510503321

Autore	Saiz Juan Carlos
Titolo	Vaccines against RNA Viruses
Pubbl/distr/stampa	Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Descrizione fisica	1 online resource (166 p.)
Soggetti	Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches,

from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts.